Shopping Cart
- Remove All
- Your shopping cart is currently empty
Cevipabulin (TTI-237) is a microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin (IC50: 18-40 nM in the human tumor cell line).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $30 | In Stock | |
5 mg | $54 | In Stock | |
10 mg | Inquiry | In Stock | |
25 mg | Inquiry | In Stock | |
1 mL x 10 mM (in DMSO) | $64 | In Stock |
Description | Cevipabulin (TTI-237) is a microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin (IC50: 18-40 nM in the human tumor cell line). |
Targets&IC50 | Microtubule (human tumor cells):18-40 nM |
In vitro | Cevipabulin (0-50 nM, 72 hours) exhibits significant activity (IC50s: 18-40 nM) against ovarian, breast, prostate, and cervical tumor cell lines. At low concentrations (20-40 nM), it induces sub-G1 nuclei, while concentrations above 50 nM result in a pronounced G2-M block [1]. |
In vivo | In mice, Cevipabulin ( 5, 10, 15, and 20 mg/kg, every 4 days for 4 cycles; i.v. and p.o.) is active against human tumor xenografts and showing dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg [1]. |
Alias | TTI-237 |
Molecular Weight | 464.82 |
Formula | C18H18ClF5N6O |
Cas No. | 849550-05-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | DMSO: 9 mg/mL (19.36 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.